Jpmorgan Chase & CO Unicycive Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 47 shares of UNCY stock, worth $23. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47Holding current value
$23% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding UNCY
# of Institutions
23Shares Held
15.9MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA3.61MShares$1.81 Million0.15% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.47MShares$1.74 Million0.64% of portfolio
-
Logos Global Management LP San Francisco, CA3.47MShares$1.73 Million0.45% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.34MShares$1.67 Million0.3% of portfolio
-
Monashee Investment Management LLC Boston, MA1MShares$500,0000.19% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $7.53M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...